NATIONAL
CANCER
INSTITUTE

NCI Cancer Bulletin
A Trusted Source for Cancer Research News
April 18, 2006 • Volume 3 / Number 16 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe


Bulletin Home

Featured Article
STAR Results: Raloxifene as Effective as Tamoxifen, Better Safety Profile

Director's Update
Minority Cancer Awareness Week: A Time to Reflect

Spotlight
NCI's Developmental Therapeutics Program: Turning Molecules into Medicine

Cancer Research Highlights
Estrogen-Only Treatment Does Not Increase Breast Cancer Risk

Discovery Shows How Kaposi's Sarcoma Virus Enters Cells

Inadequate Screening Is Linked to Breast Cancer Disparities

Funding Opportunities

Featured Clinical Trial
Studying Childhood ALL Relapse and Survival

Notes
Revised Breast Cancer Risk Assessment Tool Available

Cancer Bulletin Wins Award

The Nation's Investment in Cancer Research for FY 2007 Now Available in HTML

"Understanding NCI" Teleconference Set for April 27

DCEG Holds Town Meeting

Community Update
Conference Promotes Collaborations in Traditional Chinese Medicine Research

Bulletin Archive

Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
Featured Article

STAR Results: Raloxifene as Effective as Tamoxifen, Better Safety Profile

The long-awaited results of the largest breast cancer chemoprevention trial ever conducted provide what its leaders say is excellent news: Regular use of the anti-osteoporosis drug raloxifene (Evista) works just as well as tamoxifen at reducing breast cancer risk in postmenopausal women at high risk, but appears less likely to cause some of the potentially dangerous side effects seen with tamoxifen use.

"These results demonstrate that raloxifene represents an effective alternative for postmenopausal women at increased risk of breast cancer," said Dr. D. L. Wickerham, associate chairman of the National Surgical Adjuvant Breast and Bowel Project (NSABP), which coordinated the Study of Tamoxifen and Raloxifene (STAR).

The STAR results, added Dr. Leslie Ford, associate director for clinical research in NCI's Division of Cancer Prevention, "have immediate implications for how women view their breast cancer risk and what they can do about it. They will make breast cancer prevention more of a reality for many women."  Read more  

Director's Update

Guest Update by Dr. Sanya Springfield

Minority Cancer Awareness Week: A Time to Reflect

Each year, we learn more about the devastating impact of cancer on minority communities. Whether it is the burden of one type of cancer on a particular minority population, or disproportionate mortality when comparing minorities with whites, cancer disparities exact a huge toll on society. As long as these disparities exist, our work to eliminate suffering and death due to cancer is far from complete.

That is why overcoming cancer health disparities remains one of NCI's strategic priorities as well as one of the best opportunities we have for making an impact on cancer. The strategy calls for understanding the factors that cause cancer health disparities, working with communities to develop targeted interventions, developing interventions to enhance the integration of services for underserved populations, and working to develop a cadre of researchers and clinicians who can effectively address cancer disparities.  Read more  

The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI). NCI, which was established in 1937, leads the national effort to eliminate the suffering and death due to cancer. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information on cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.

NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.

Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov